Steven B. Kanner

Biochemistry, Genetics and Molecular Biology · Life Sciences

43h-index7.2kcitations219works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(37), CAR-T cell therapy research(33), RNA modifications and cancer(28), T-cell and B-cell Immunology(27), Cancer Research and Treatments(26)

Publications219 total

Table S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Supplementary Data Legend LS1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Table S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
2025Open Access
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
Journal of Clinical Oncology·2024· 8 cited
Figure S7. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
Data from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
Figure S4. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
Figure S6. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
Figure S6. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
Figure S1. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
Figure S3. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
Figure S1. from High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models
2024Open Access
page 1 of 11Next →

Frequent Co-authors

Gary L. Schieven(10), Alejandro Aruffo(9), Jason M. Foulks(6), Juan J. Pérez‐Villar(6), Joel C. Barrish(6), Jeffrey A. Ledbetter(5), Gena S. Whitney(5), J A Ledbetter(5), Michael V. McCullar(5), Kim W. McIntyre(5), David J. Shuster(5), James C. Lin(5), Robert V. Moquin(5), Arthur M. Doweyko(5), John Wityak(5), J. Thomas Parsons(4), Albert B. Reynolds(4), Rebecca N. Nix(4), Tai-An Lin(4), Jagabandhu Das(4)